Retrospective study of 177Lu-DOTATATE in well-differentiated high-grade neuroendocrine tumors
Latest Information Update: 02 Mar 2021
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium